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Abstract
Purpose—To summarize the recent literature describing the application of modern technologies 
in the study of patients with geographic atrophy (GA) secondary to age-related macular 
degeneration (AMD).
Methods—Review of the literature describing the terms and definitions used to describe GA, 
imaging modalities used to capture and measure GA, and the tests of visual function and 
functional deficits that occur in patients with GA.
Results—In this paper we describe the evolution of the definitions used to describe GA. We 
compare imaging modalities used in the characterization of GA, report on the sensitivity and 
specificity of the techniques where data exist, and describe the correlations between these various 
modes of capturing the presence of GA. We review the functional tests that have been used in 
patients with GA, and critically examine their ability to detect and quantify visual deficits.
Conclusion—Ophthalmologists and retina specialists now have a wide range of assessments 
available for the functional and anatomic characterization of GA in patients with AMD. To date, 
studies have been limited by their unimodal approach and we recommend that future studies of 
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GA use multimodal imaging. We also suggest strategies for the optimal functional testing of 
patients with GA.
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Age-related macular degeneration; geographic atrophy
Introduction
In patients with age-related macular degeneration (AMD), geographic atrophy (GA) 
manifests as sharply demarcated areas of loss of the retinal pigment epithelium (RPE), 
choriocapillaris, and overlying photoreceptors that develop primarily in the macular retina 
and expand over time.1, 2 With no proven treatments, GA represents an important unmet 
need as it leads to visual impairment and affects more than 5 million people worldwide.3 It 
has been estimated that by the year 2020, a projected 196 million individuals will suffer 
from AMD, and that this number will increase to 288 million by the year 2040.4 A 2014 
meta-analysis reported that approximately half of patients with late-stage AMD have GA.4 
The prevalence data on GA in this study were limited, and the authors noted that this 
estimate was based on data from only 8 of the 39 population based studies included in the 
analysis. A more recent meta-analysis based on data in the United States reported that the 
incidence of GA and neovascular AMD were 1.9 and 1.8 per 1000 American whites aged 
≥50 years.5 Prevalence rates for the two forms of advanced AMD were comparable across 
all age groups.
The natural history of AMD has been studied extensively. In the early stages, characteristic 
findings are the presence of drusen, which can manifest with or without RPE irregularities 
(hypopigmentation or hyperpigmentation).6 These features do not result in overt vision loss 
although functional deficits can be detected using appropriately designed psychophysical 
tests. The risk of progression of early AMD to intermediate and late stages may depend on 
ocular factors such as RPE depigmentation, drusen size, 7, 8 and presence of reticular 
pseudodrusen (RPD). 9 Higher prevalence of RPD has been reported in patients with GA 
compared with early, intermediate, or no AMD,10–13 with the presence of RPD conferring a 
hazard ratio for progression to GA as high as 4.9.9 As AMD progresses there can be 
profound effects on visual function (e.g. when GA involves the central retina), including the 
presence of scotoma in the visual field, impaired facial recognition, and compromised 
reading ability.1
Some data suggest that in patients who have developed GA, more than a third will lose three 
or more lines of visual acuity on the standard eye chart within 2 years, due to the progressive 
loss of retinal tissue.14 Vision loss is more likely when the GA involves the central macula; 
more than half of patients with GA encroaching upon the fovea will suffer this severity of 
vision loss in the same time frame when compared to extrafoveal GA.14 Even when GA is 
not center-involving, patients can suffer significant deficits in visual function, such as 
compromised reading ability and impaired vision in dim lighting.15 The occurrence of GA 
with concomitant choroidal neovascularization (CNV) is not uncommon, and is associated 
with an even greater risk of severe vision loss than GA alone.7, 16, 17 Sunness et al showed 
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that 86% of eyes with GA that developed CNV lost three or more lines of visual acuity over 
2 years, compared to only 27% in eyes with GA that did not develop CNV.18
The pathophysiology of GA is influenced by a number of factors including age, smoking, 
and body mass index. Genetic susceptibility is now increasingly recognized as an important 
contributor to AMD and more than 19 genetic polymorphisms have been demonstrated to 
influence AMD risk. Of note, five of these genetic variants are encoded by genes that 
modulate the complement system, and four of those are within the alternative complement 
pathway.19–21 Inflammatory processes are hypothesized to play a key role in AMD, 
including those mediated by complement,22–26 and may contribute to the eventual loss of the 
choriocapillaris, photoreceptors, and retinal pigment epithelium (RPE) cells.27–29
In the absence of RPE, photoreceptors become nonviable and therefore areas of GA that are 
identified using imaging techniques correspond to scotomas in the visual field.30 In a 
proportion of eyes, GA can grow in a unique foveal-sparing pattern that tends to involve the 
fovea only late in the course of the disease.1, 15, 16, 31, 32 This type of GA may not result in 
any worsening of best-corrected visual acuity (BCVA) as the center of the fovea is 
preserved. BCVA is widely accepted by the clinical community and regulatory authorities 
worldwide as a key measure of visual function and represents the gold standard by which the 
efficacy of treatment is judged. However, BCVA is a measure of central acuity of the fovea 
and does not assess all nuances of comprehensive visual function. The drawback of relying 
solely on BCVA as a measure of ocular health was shown elegantly by Sunness et al who 
demonstrated that when GA was present in eyes with BCVA 20/50 or better, other features 
of visual function were considerably impaired. These included contrast sensitivity, low-
luminance BCVA, and reading speed.15 Impairment of visual function can also be detected 
and monitored using microperimetry, even in patients with preserved BCVA.33, 34 BCVA by 
itself does not adequately capture the visual deficits experienced by patients with foveal-
sparing GA. Therefore clinical studies involving patients with GA that aim to quantify 
changes in visual function and correlate them with disease worsening will need to 
incorporate additional endpoints that account for the underlying pathophysiologic processes 
of the disease.
A number of existing and new technologies enable the quantitative morphological 
assessment of GA, including color fundus photography (CFP), fundus autofluorescence 
(FAF), and optical coherence tomography (OCT). In addition, the armamentarium of 
functional assessments beyond BCVA now include multifocal electroretinography (mfERG); 
microperimetry, low luminance visual acuity (LLVA), reading speed, contrast sensitivity, and 
patient-centered outcome measures. In this review, we will summarize the recent literature 
describing the application of these techniques to the study of patients with GA secondary to 
AMD.
Methods
PubMed literature searches were conducted to identify articles describing the study of GA 
secondary to AMD using anatomic or functional measures. Broad initial searches 
encompassed all techniques for evaluation of retinal anatomy; anatomic techniques 
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identified for coverage in the review (CFP, FAF, angiography, and OCT) were those that are 
most widely implemented in the study of GA. Literature searches for data describing 
functional measures were based on broad initial searches for studies assessing visual 
function in AMD, with subsequent searches deriving from terms and references generated 
within these results based on prevalence of use (e.g. mfERG, microperimetry, LLVA, reading 
speed, and patient-reported outcome measures). Search terms encompassed the broader 
AMD population to capture titles not explicitly mentioning GA but possibly containing this 
subgroup (e.g. ((age[ti] AND macular[ti] AND degeneration[ti]) AND (fundus[ti] AND 
(color[ti] OR autofluoresc*[ti]))). In addition to PubMed searches, a search of 
clinicaltrials.gov was conducted to tabulate active GA trials as of March 1, 2016 with 
clinical endpoints involving GA lesion assessment.
Morphological Measures of Geographic Atrophy
The criteria for diagnosis of GA differs across grading systems and imaging modality. The 
best established grading system, which was developed in the 1980s, was based on color 
image grading. However, the definitions have not remained constant and there has been 
continual change in the parameters used to define the presence of GA on color fundus 
images. The first clear definition of GA was proposed by the Wisconsin Age-Related 
Maculopathy Grading System in which GA was defined as an area of pallor in the fundus 
with visibility of the underlying choroidal blood vessels and sharply defined borders, 
occupying a diameter ≥175 μm.6, 35, 36 Subsequently the definitions were used to identify 
the presence of GA by the International Age-Related Maculopathy Grading System, and the 
Age-Related Eye Disease Study (AREDS). However, other studies have used larger 
definitions of GA. The Complications of Age-Related Macular Degeneration Prevention 
Trial (CAPT) specified a diameter >250 μm for definition of GA,37 and in the AREDS2 
study the minimum diameter of the area was increased to 433 μm.38 Currently there is no 
international consensus on the minimum diameter for the diagnosis of GA.
In addition, changes have been proposed in the grading of AMD severity level with regards 
to the presence of GA. In the AREDS grading system, the presence of GA qualifies patients 
as having either intermediate or advanced AMD, depending on whether or not there is 
central involvement.6 In the classification system recently developed by the Beckman 
Initiative for Macular Research, the presence of any GA regardless of location qualifies as 
evidence of advanced AMD.39
Color Fundus Photography
Morphological endpoints are important outcomes in clinical trials of all stages of AMD, as 
they are based on directly measurable physical characteristics. As such they generate 
reproducible, reliable, objective clinical information. Morphological endpoints are 
unaffected by patient compliance, comprehension, or cognitive status, which can influence 
psychophysical or functional endpoints.
Seminal research in the characterization of GA by CFP was accomplished in the natural 
history studies by Sunness et al, and by the AREDS research group.6, 40, 41 Using color 
images captured on 35 mm film, these studies helped to shape the methodology for 
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quantification of GA area. AREDS recruited more than 4700 participants with and without 
AMD for the study of the natural history and the role of mineral and antioxidant 
supplements in disease progression.42 The CFP grading system implemented in AREDS was 
an extension of the Wisconsin Age-Related Maculopathy Grading System.35 A standardized 
grid was used for size estimation of the retinal features of early and late AMD; eyes were 
then assigned to one of four severity levels according to the size and type of abnormalities 
observed on CFP.6 In the initial AREDS classification scheme, patients with GA were 
classified as either severity level 3 (intermediate) or 4 (advanced) based on foveal 
involvement; more recently, Ferris et al have proposed the updated and simplified Beckman 
AMD classification scheme in which eyes with GA regardless of location are categorized as 
late AMD (Figure 1).39 At the time of AREDS, grading was performed by trained, certified 
technicians under the supervision of ophthalmologists, and this method continues to be used 
in present studies. More recently with the advent of digital photography, several image 
analysis technologies are being used to explore the possibility of automated delineation of 
the area of GA.43–47
In patients with AMD, areas of GA are identified with CFP in part by their distinctly 
different color (depigmented) compared to adjacent areas of healthy retina (Figure 1), as 
well as by the presence of sharply demarcated borders and increased visibility of choroidal 
vessels.40 Key characteristics of imaging techniques for quantitation of GA include the 
ability of the technique to reproducibly measure GA area and ability to predict progression 
of GA area. In this regard, CFP has certain limitations that have led to the complementary 
use of other imaging modalities for the quantitation of GA area. One important limitation of 
CFP is the limit of resolution with this technology. CFP uses light in the visible spectrum to 
capture the fundus image and identify the boundaries of the various structures by their color. 
However, it is challenging to demarcate areas of distinct morphology but indistinct color. For 
example, with CFP it is difficult to distinguish GA that has a pale yellowish hue from either 
depigmented RPE or areas of drusen that also appear yellowish.48 Good stereophotography 
may facilitate quantification by allowing the borders of GA lesions to be seen more sharply; 
however, it is not always possible to obtain high-quality stereophotographs in the context of 
large studies. Therefore the reproducibility of GA measurements with CFP can be less 
compared to other methodologies such as FAF.49 As a result, other imaging technologies 
have come into use as adjunctive measures of GA morphology. Another limitation of CFP is 
difficulty in visualizing reticular pseudodrusen, which are known to be associated with an 
increased risk of GA.
Fundus Autofluorescence
FAF is the current standard imaging technology for the morphological assessment of GA, 
and is often used in conjunction with CFP. In this technique, the fluorescence signal 
originates from lipofuscin, a naturally occurring compound within RPE cells.50 Lipofuscin 
is a heterogeneous, cross-linked material composed of oxidized protein, lipid, metal ions, 
and sugar residues that form intracellular aggregates in RPE cells.51, 52 Lipofuscin absorbs 
light of a specific wavelength and emits the absorbed light at a different wavelength,53 and 
this property is exploited to image the RPE (Figure 2). In the healthy eye, the pattern of 
autofluorescence is distributed uniformly, diminishing toward the fovea due to absorption by 
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macular pigment. In eyes with GA, distinctly dark areas are observed where the atrophy of 
lipofuscin-containing RPE cells leaves an absence of fluorescent signal. Due to the 
contrasting boundaries between areas of absent and surviving RPE in FAF images, this 
modality offers better delineation in the identification of atrophic regions.49, 54, 55 For 
imaging of central GA, the use of green-light FAF may offer a more accurate means of 
measuring GA area than blue-light FAF.56
In addition, FAF provides an important diagnostic not currently available with other imaging 
modalities.55 In the junctional zone (i.e., the boundary between dead and surviving RPE 
regions), bright areas of hyperfluorescence are often observed. These hyperfluorescent areas 
are believed to represent regions of cells that are stressed and more likely to become 
atrophic.57, 58 In support of this observation is the finding that abnormal autofluorescence at 
the boundary of the dead and surviving RPE predicts the risk of GA progression,58, 59 and 
furthermore specific patterns of hyperfluorescence also predict the risk of GA worsening 
(Figure 2).55, 60, 61
The predictive power of FAF imaging makes it a useful assessment for the study of GA in 
clinical trials, not only for the evaluation of treatment efficacy, but potentially for defining 
inclusion criteria. For example, use of FAF for identification of eyes at greater risk for rapid 
growth of GA area could allow for selection of a patient population that enables a shorter 
trial duration, requires fewer patients, and still allows for appropriate statistical power.58
Given its more recent emergence and adoption in clinical practice, characterization of GA by 
FAF has been quantitatively evaluated in comparison with fundus photography. In a single-
site study of 10 patients with GA, we (S.R. Sadda, Doheny Image Reading Center) 
compared the agreement between GA area measured by masked readers at a reading center 
using FA and CFP, and found excellent agreement between the two imaging modalities 
(Spearman correlation, r = 0.986).62 In this study, we showed that GA areas obtained by 
FAF were larger by 0.178 ± 0.45 mm2 (P = 0.0001).
Khanifar et al evaluated data from 72 eyes with GA for which FAF images had been 
acquired and graded along with CFP photos.49 To compare these imaging modalities, three 
independent graders calculated the total area of GA using both techniques. The results 
showed that the two instruments had very good agreement. Differences between GA area as 
measured by FAF and CFP were close to zero, with FAF-CFP correlation coefficients of 
0.85, 0.87, and 0.93 across the three graders. In this study a small (nonsignificant) trend was 
observed; in eyes with very little GA, FAF tended to measure larger areas than CFP. The 
authors note that the enhanced contrast of FAF may allow greater sensitivity versus CFP for 
detection of small areas of atrophy, while this enhanced sensitivity may be accompanied by 
somewhat reduced accuracy in patients with very small regions of atrophy (potentially 
overestimating the actual GA area to some extent).49, 63 However, the average measurement 
differences between imaging modalities was small.
In the Geographic Atrophy Progression (GAP) study, FAF and CFP measurements were 
available for 321 patients.61 From baseline through 18 months, CFP measured significantly 
larger GA lesion areas than FAF, but the correlation between the two modalities was very 
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high (r=0.89–0.94). In addition, the lesion size change from baseline was similar as 
measured by FAF and CFP at month 6 (0.78–0.88 mm2, P=0.164), month 12 (1.57–1.85 
mm2, P=0.023), and month 18 (3.17–3.14 mm2, P=0.944). In practice and in clinical studies, 
FAF continues to be used as an integral measurement for the observation of GA area in 
patients with AMD (Table).
A downside of FAF imaging is that the bright imaging light may be uncomfortable for 
patients, particularly when using shorter-wavelength blue light. Concerns have been raised 
that blue light (even within the ANSI standards) may be harmful for patients with 
susceptible diseases of the retina.64–66 Also, due to absorption by macular pigment, it is 
usually not possible to determine the extent of foveal involvement by the atrophic lesion 
using blue light autofluorescence alone.
Optical Coherence Tomography
Imaging techniques such as CFP and FAF provide 2-dimensional (2-D) images taken from 
an axial perspective, with limited depth information. OCT on the other hand is a 
tomographic technique that yields 2-D and 3-D high-resolution information. Most 
commonly, 2-D high-resolution OCT B-scans are used to provide important cross-sectional 
information for assessment of retinal layers (Figure 3A), evaluation of GA lesion area 
(Figure 3B), and measurement of GA lesion growth (Figure 3C). OCT data can also be 
summed in the axial direction to yield en face projection images for comparison with CFP or 
FAF. In en face OCT, 3-D images are constructed from a series of 2-D longitudinal cross-
sections of retinal layers (B-scans).
Time-domain OCT became commercially available in 1996 with the Zeiss Stratus (Carl 
Zeiss Meditec, Dublin, CA). This instrument provided ophthalmologists the opportunity to 
view cross-sectional details of the human retina in vivo for the first time.67 Although this 
was a significant advancement in the diagnosis and study of retinal disease, the resolution 
and technical capabilities of time-domain tomography limited its application.68 By 2003 
successive advancements in OCT technology led to the commercial availability of spectral 
domain OCT (SD-OCT), which has sufficient speed and resolution for better assessment of 
individual retinal layers and has enhanced our understanding of the cellular events that lead 
to GA.67
In healthy eyes, the individual layers of the retina appear on 2-D OCT as well-defined bands 
(Figure 3A). The characteristic defects of GA manifest as a sharply demarcated region of 
degradation in the RPE and photoreceptor layers, and increased reflectivity from the 
underlying choroid and choriocapillaris (Figure 3B).69 Thinning and apposition of the 
overlying nuclear layer is also evident above the areas of RPE atrophy.70 In many eyes with 
GA, wedge-shaped hyporeflective structures between Bruch’s membrane and the outer 
plexiform layer may become evident on OCT.71, 72 These structures could be useful for 
defining the OCT boundaries of photoreceptor layers, which may be important in clinical 
trials of therapies that aim to preserve the viability of this retinal layer in patients with GA.72
The high-resolution imaging of retinal microstructure afforded by SD-OCT is also helpful in 
the assessment of the progression and pathophysiology of GA.70, 73 In one study, data were 
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compared in 20 subjects with GA for whom both SD-OCT macular volume and FAF images 
had been acquired (on separate instruments).73 This study demonstrated good agreement 
between GA area calculated by automated analysis of SD-OCT data and that calculated by 
FAF. In another study, a prospective evaluation of 46 eyes with GA showed that combined 
FAF and SD-OCT techniques using the Spectralis instrument (Heidelberg Engineering, 
Heidelberg, Germany) facilitated the accurate serial imaging of the same retinal location 
across multiple office visits over a period of months. This technique revealed previously 
undetectable dynamic changes in the retina of patients with GA.70 More recently, a false-
color fusion method has been developed to allow simultaneous visualization and 
quantification of both drusen and GA in SD-OCT images.74
The rate of GA area progression in eyes with AMD has been evaluated using SD-OCT to 
image the photoreceptor and RPE layers of the retina.75 Thirty patients with GA were 
followed for 1 year, with assessment of GA area at baseline and worsening over time 
measured by three graders using an axial projection of the sub-RPE layer. Separately, the 
SD-OCT signal corresponding to the en face photoreceptor layer was also visualized. When 
these two layers were superimposed to examine the relationship between photoreceptors and 
GA, areas showing degradation of the photoreceptor ellipsoid zone (or inner segment-outer 
segment junction line) predicted where the GA area would later expand. The authors noted 
the important implications of this technique for future clinical trials that use reduction of GA 
progression as a primary endpoint. For example, it was suggested that if photoreceptor 
degradation inevitably leads to growth of GA into these areas, then regardless of effective 
intervention, this additional area of photoreceptor loss should be taken into account and 
adjusted for when calculating the primary outcome measure.
At present, these emerging SD-OCT methods for assessment of GA area and retinal 
morphology are not optimized nor standardized for extensive use in clinical trials, though 
they hold promise for the future. As experience with new SD-OCT protocols and algorithms 
increases and automated software programs are refined, the ability to study and monitor GA 
lesions by SD-OCT will become more widespread. OCT imaging may also contribute to a 
better understanding of underlying pathologic mechanisms in AMD and GA, may suggest 
new biomarkers related to disease progression, and might potentially indicate new 
therapeutic targets in AMD.
Contrast-Based Imaging (Angiography)
Fluorescein angiography (FA) and indocyanine green angiography (ICGA) are techniques 
commonly used to assess neovascularization in patients with neovascular AMD.76–78 FA 
involves intravenous administration of the dye fluorescein, followed by fluorophore 
excitation with blue light. As the dye reaches the eye, selective imaging of the retinal 
vasculature reveals abnormal blood vessel characteristics (e.g., retinal nonperfusion) and 
subretinal vascular defects (e.g., CNV lesions) as leakage of the dye diffuses through the 
retina. While the primary role of FA in the assessment of GA is to exclude the presence of 
CNV, angiography can also provide high contrast for delineation of the GA lesion as areas of 
atrophy typically show well-demarcated areas of staining, whereas areas of depigmentation 
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or RPE disturbance may only show poorly demarcated hyperfluorescence that can fade over 
time.
Direct imaging of the choroidal vasculature with FA is hampered by rapid leakage from the 
overlying choriocapillaris and absorption of dye fluorescence by RPE. In contrast, the ICGA 
emission wavelength is longer and less prone to absorption by RPE. Its pharmacodynamics 
are characterized by nearly complete binding to plasma protein, which slows efflux from the 
choriocapillaris, resulting in better imaging of subretinal vasculature.79
In patients with GA, ICGA reveals lesion boundaries in addition to distinct pathophysiologic 
findings that are not evident using other imaging modalities.80 These may include direct 
visualization of the choroidal vasculature81 and aneurysms of choroidal vessels.82 ICGA 
may aid in differential diagnoses, for example through differentiation of GA versus occult 
CNV lesions83 or Stargardt disease.84 Age at clinical presentation may be a helpful 
distinction between GA due to AMD and Stargardt disease, whereas imaging with FA and 
ICGA reveals striking differences between the two modalities. Stargardt atrophy most often 
presents as hypofluorescence on both FA and ICGA (dark atrophy), whereas GA lesions due 
to AMD typically present as hypofluorescence only on FA.84
Functional Tests
Multifocal Electroretinography
Direct measurement of photoreceptor signaling within the retina in response to a light 
stimulus can be measured using focal electroretinography (fERG) and mfERG.85, 86 This 
technology uses electrodes in contact with the cornea during testing. In multifocal 
techniques, upon application of light stimuli in regular patterns that scan the retina, 
photoreceptor signaling is detected by the corneal electrode. By varying the intensity of the 
light stimulus, the functionality and sensitivity of specific areas of the retina can be mapped 
(Figure 4).
A growing body of literature has described the application of this technique to the study of 
eyes with AMD. One of the earliest applications of mfERG in AMD demonstrated that this 
technique can be used to detect differences in retinal electrophysiology in patients with early 
AMD compared with controls.87 Fifteen eyes with early AMD and drusen were studied with 
mfERG and compared with both asymptomatic fellow eyes and age-matched controls. 
Measurable differences in mfERG signals were detected in eyes with early AMD, 
demonstrating the utility of this technology for early detection of visual defects in patients 
with AMD.
A key retinal abnormality in patients with GA is the loss of photoreceptors, visible on SD-
OCT.1, 75 Retinal function data attainable via mfERG have been compared with SD-OCT 
abnormalities corresponding to the photoreceptor layer.88 In 29 patients with early AMD, 
the intensity of the photoreceptor layer on SD-OCT was significantly diminished in eyes 
with early AMD versus control eyes, and was significantly correlated with mfERG signal. In 
this study the morphological observation of photoreceptor degradation on SD-OCT was 
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corroborated by loss of retinal function on mfERG, demonstrating the utility of mfERG for 
the study of retinal pathophysiology in AMD.
Considering the high prevalence of concomitant RPD in eyes with GA, and the potential role 
of RPD in the pathophysiology of GA, the effects of RPD on retinal function may be 
important as an early measure of visual function impairment along the AMD disease 
continuum. Some studies have begun to explore the effects of RPD on visual function using 
mfERG. Alten et al evaluated the effect of RPD on retinal function as measured by mfERG 
at baseline and at 12 month follow-up.89, 90 In these two studies, fellow eyes had various 
manifestations of AMD such as drusen, CNV, or GA, but study eyes had only RPD. The 
results demonstrated that mfERG sensitivity was not significantly altered by the presence of 
RPD alone, when compared with healthy control eyes. However, another study found that 
impaired mfERG sensitivity was detectable in eyes with RPD and concomitant intermediate 
AMD.91 Univariate and multivariate analyses showed that sensitivity impairment in patients 
with RPD was detectable in mfERG implicit time, but not in signal amplitude. Considering 
their results against existing literature, these authors point out the potential confounding 
effects of instrumentation and methodology on the consistency of mfERG results across 
studies. Thus, the use of mfERG to evaluate the effects of RPD on retinal function in eyes 
with AMD remains a subject of ongoing research.
Psychophysical Tests of Visual Function
Electrophysiology is objective, and does not rely on patient cognition, measuring 
precognitive aspects of the visual system at the level of the retina. Other techniques of 
function integrate patient cognitive involvement in the measurement process to provide 
information on visual perception and deficit. Historically, the simplest and most widely used 
psychometric assessment of visual function has been BCVA. However as noted earlier, in 
patients with GA, changes may become evident in several measures of visual function 
before deterioration in BCVA occurs, underlining the importance of multifactorial 
assessment of visual function. The aim of this section is to describe the recent GA literature 
regarding other psychometric techniques.
Low Luminance Visual Acuity and Contrast Sensitivity
Another visual acuity metric that has been evaluated in patients with GA is LLVA. In this 
technique the amount of light transmitted (optical intensity) can be reduced using neutral 
density filters with a set attenuation placed over the eye to be tested, and the letters seen on a 
standard illuminated Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity 
chart are recorded. Because of the lower luminance created by the filter, LLVA scores are 
necessarily lower than BCVA and the magnitude of the difference between BCVA and LLVA 
(defined as the low luminance deficit [LLD]) reveals visual function abnormalities that 
would not otherwise be apparent by measuring standard BCVA alone. Sunness et al showed 
that in 91 patients with GA, LLD was a strong predictor of BCVA loss over 2 years, 
independent of baseline BCVA.92 Even among patients with good baseline BCVA (20/50 
Snellen or better), the relative risk of three-line loss of BCVA was 2.88 (95% CI 1.13–7.35) 
for patients with the worst LLD; 55% of patients with worse LLD lost 3 or more lines of 
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vision at 2 years compared to only 19% with smaller LLD. This study demonstrated that 
LLVA is an important outcome to be included in clinical trials of patients with GA, and may 
be a more sensitive measurement for assessing the risk of visual decline than standard 
BCVA alone.
A similar and related psychometric outcome is contrast sensitivity, often measured using the 
Pelli-Robson contrast sensitivity chart.93 In this chart, the letters are all the same size, 
diminishing in contrast from black to grey and further to lighter shades that eventually 
cannot be distinguished against a white background. Other instruments show alternating 
black and white lines on a screen (sinusoid gratings).94 In the GA natural history study 
conducted by Sunness et al, patients with GA and good BCVA (20/50 Snellen or better) had 
significantly worse contrast sensitivity compared with AMD patients who did not have 
GA.15 Contrast sensitivity and LLD both may be used to detect abnormal visual function in 
patients with good BCVA.
Microperimetry
LLVA and contrast sensitivity measure the effect of luminance and contrast on overall visual 
function, but do not allow for more detailed assessment of function across specific areas of 
the retina. Because the specific location of GA lesions in the macula or fovea can dictate 
visual outcomes, this level of detail is important for functional assessments of vision in 
patients with GA. In recent years, the availability of commercial microperimetry instruments 
has facilitated the psychometric study of retinal function in greater detail. Akin to mfERG, 
in microperimetry, specific areas of the retina are stimulated with points of light, and the 
patient presses a button to acknowledge perception of the stimulus. In addition to identifying 
functional and nonfunctional areas, stimulus intensity is varied to also identify the relative 
sensitivity of specific areas of the retina. The fundus is monitored via infrared camera and 
the fixation point is continuously tracked; thus the sensitivity of the visual field can be 
mapped to the fundus photo and compared to images obtained with other modalities.
Microperimetry has revealed several key pathophysiologic findings in GA (Figure 5). One 
study of 18 eyes with GA showed that microperimetric assessment of visual function 
significantly correlated with progression of the GA lesion area over a 2-year period.95 The 
number of scotomatous points identified with microperimetry increased over time, and was 
significantly associated with growth in the GA lesion area. Importantly, this study showed 
that the sensitivity of functional retina also decreased over time, and this loss of sensitivity 
was widespread and not limited to areas surrounding GA lesions. Other studies have 
reported similar findings. For example, although specific measurement of rod function in 
patients with GA has been relatively unexplored because instrumentation has not been 
readily available, evidence from histologic studies and rod-targeted perimetry suggests that 
early loss of rod photoreceptors may be common even at locations far removed from GA 
lesions.96, 97
Like mfERG, the utility of microperimetry for assessment of visual function deficits due to 
the presence of RPD has been reported. Forte et al showed that eyes with only RPD and 
preserved visual acuity had reduced light sensitivity on microperimetry, compared with 
control eyes having early AMD.98 Another study evaluated RPD in AMD eyes with small 
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drusen, and also found reduced sensitivity on microperimetry compared with early AMD 
controls.99 However, RPD did not affect microperimetry sensitivity in eyes with bilateral 
intermediate AMD. Similar to the application of mfERG for the assessment of retinal 
function, the role of RPD in AMD is still a key research question. Further studies are needed 
in patients with AMD to fully understand the effect of RPD on visual function as measured 
by mfERG and microperimetry. Microperimetry studies have also revealed detail on changes 
in retinal sensitivity in the pathogenesis of GA. Using microperimetry to assess retinal 
function in the junctional zone of hyperfluorescence surrounding GA lesions, it has been 
shown that regions of elevated FAF had significantly lower sensitivity to light stimuli 
compared with regions of normal FAF.100 Similar results were reported by Scholl et al.101 In 
this study, authors further differentiated retinal sensitivity in hyperfluorescent regions under 
photopic and scotopic conditions to selectively probe the sensitivity of rod and cone 
photoreceptors. Their results demonstrated that scotopic sensitivity loss in hyperfluorescent 
regions far exceeded photopic loss. Taken together, these data suggest that hyperfluorescent 
regions of the retina outside of GA lesions demarcate areas of impaired photoreceptor 
function, and demonstrate the importance of microperimetry in monitoring the development 
and progression of GA.
Reading Speed
Reading speed can be objectively measured, typically calculated from the number of 
correctly read words in a paragraph of random words presented for a short, fixed amount of 
time.102 Two commonly used assessments are the MNREAD and Radner reading charts that 
have been validated in a number of languages.102–105 The natural history study conducted by 
Sunness et al showed that even in AMD patients with BCVA ≥20/50, reading speed was 
significantly poorer in those with GA compared with those having early or intermediate 
AMD.15, 92 In these patients, poor reading speed was also predictive of future deterioration 
in BCVA.
Self-Reported Visual Functioning and Quality of Life
Although psychophysical tests (i.e., BCVA, LLVA, contrast sensitivity, microperimetry, 
reading speed) can reveal specific visual function deficits, they do not capture the entire 
range of effects that a disease might incur. Therefore patient-centered outcome measures 
have been developed. These instruments contain a number of items (questions) asking the 
subject to report the degree of disability experienced, which is recorded on a graded 
categorical scale. The instruments consist of a variety of domains that explore specific 
aspects of vision such as near function, distance function, color, etc. Various instruments 
have been used to examine the effects of visual function deficits on the daily activities of 
patients with GA.106, 107
A widely used psychometric instrument for assessment of vision-related quality of life is the 
25-item Visual Function Questionnaire (VFQ-25) developed by the National Eye 
Institute.108, 109 Created in 1998 as a 51-item instrument, it has since been refined to 25 
items to capture patient-centered vision-related health status among individuals with chronic 
eye diseases. This questionnaire measures the influence of visual dysfunction on aspects of 
daily life (e.g., reading the newspaper, finding items on a crowded shelf, driving), as well as 
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broader topics (e.g., emotional well-being, social functioning). While VFQ-25 has been 
widely implemented in studies involving patients with AMD, the literature has focused on 
the neovascular AMD population rather than those with GA or GA lesion area worsening. 
Similarly, other instruments such as the Visual Function Index (VF-14),110 Short Form 
Health Survey (SF-36),111 and MAC-TSQ have not been well-characterized in the GA 
population.
Recently a new psychometric instrument for assessment of functional reading has been 
developed specifically for use in patients with GA. The Functional Reading Independence 
(FRI) Index is a 7-item questionnaire that evaluates the effect of GA on a patient’s ability to 
independently perform reading activities. The validation of this instrument was recently 
reported.112 Among other measures of validity, the FRI Index score correlates with GA 
lesion size and VFQ-25 score, such that patients with larger GA lesions or lower VFQ-25 
scores demonstrate significantly lower mean scores on the FRI Index.112 The FRI Index was 
also sensitive to increases in GA lesion area.113 Moving forward with the study of functional 
visual impairment in patients with GA, the FRI Index is currently being implemented in 
phase 3 GA clinical trials. This instrument is publicly available through Mapi Research 
Trust. Requests for information or access to the questionnaire may be sent to 
PROinformation@mapi-trust.org.
Clinical Endpoints in Ongoing GA Trials
For ongoing and future clinical studies of GA, multimodal assessments will facilitate a 
comprehensive database of information to further our understanding of this disease. The 
largest ongoing registered phase 3 trials in geographic atrophy are the interventional Chroma 
and Spectri studies (Genentech/Hoffmann-La Roche). Chroma (NCT02247479) and Spectri 
(NCT02247531) are evaluating the efficacy and safety of lampalizumab, a monoclonal 
antibody antigen-binding fragment (Fab) targeting complement Factor D in patients with 
GA. The primary endpoint of these studies is mean change in GA area assessed by FAF, and 
as part of a comprehensive assessment these studies will also evaluate potential treatment 
effect differences using CFP, OCT, microperimetry, reading speed, LLVA, VFQ-25, and the 
FRI Index.
The ongoing Phase 2b/3 trial SEATTLE (NCT01802866) is evaluating the visual cycle 
modulator emixustat hydrochloride in patients with GA. This 24-month study will compare 
the efficacy of emixustat compared with placebo, using a primary endpoint of change from 
baseline in total GA lesion area. Anatomic endpoints utilized in the phase 2 study included 
FAF, fundus photography, and FA, thus it is likely these endpoints will be carried forward in 
SEATTLE. The 24-month Phase 2/3 trial TOGA (NCT01782989) will assess the efficacy of 
doxycycline versus placebo in GA patients, with a primary outcome of GA enlargement rate. 
Several other phase 2 studies are also underway (Table), which will evaluate GA lesion area 
as their primary endpoint. Taken together, these studies will help further our understanding 
of GA, they will improve characterization of GA and clarify the most sensitive, and 
appropriate imaging and functional endpoints to monitor disease progression and evaluate 
potential treatment responses.
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Summary
The unique pathologic mechanisms of GA secondary to AMD have important implications 
for the evaluation of visual function in patients with this disease. As a late-stage 
manifestation of AMD, GA develops gradually with the formation of scotomas that spare the 
fovea initially, expanding into the central visual field late in the course of 
disease.1, 15, 16, 31, 32 The most common assessment of visual function, BCVA, usually fails 
to reveal the functional deficits experienced by patients with foveal-sparing GA. More 
appropriate measures of visual function that can topographically map retinal sensitivity and 
or provide a more global metric of macular function are needed as sensitive outcome 
measures in GA clinical trials.114
Consequently, a multimodal approach to the assessment of visual function is most 
appropriate for clinical endpoints in trials involving patients with GA. As highlighted in this 
review, there have been remarkable advancements in technologies for assessment of GA 
functional and anatomic deficits, as well as the means of their application. A consensus 
panel on the quantification of visual acuity has previously suggested that the combined use 
of measurements such as contrast sensitivity, reading speed, microperimetry, and 
psychometric questionnaires along with BCVA should be used to more fully assess visual 
impairment.115 The primary and most rigorous outcomes for tracking disease progression in 
patients with GA are anatomic endpoints such as CFP, FAF, and OCT. Clinical studies using 
a multimodal imaging approach will be the most effective means of evaluating the role of 
RPD in GA, since this approach is best suited to account for the challenges of accurate 
diagnosis and quantitation of RPD.116
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Brief Summary Statement
Ophthalmologists and retina specialists now have a wide range of functional and 
anatomic assessments available for the characterization of geographic atrophy in patients 
with age-related macular degeneration. This review summarizes the recent literature 
describing the application of modern techniques for the study of geographic atrophy.
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Fig 1. 
AREDS macular grid and Beckman AMD severity grading system using CFP. Brighter areas 
on CFP correspond to GA and loss of pigmented epithelium. Standardized circles C0 (63 
μm) and C1 (125 μm) are used for determination of drusen size.
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Fig 2. 
Assessment of GA using FAF. In a healthy retina, lipofuscin autofluorescence is distributed 
uniformly in a pattern that diminishes toward the fovea. In contrast, distinct dark areas are 
evident in the eye with GA, where death of lipofuscin-containing RPE cells leaves a region 
of hypofluorescence. Different FAF patterns in the junctional zone have been correlated with 
varying risk of GA progression.55 IQR, interquartile ratio.
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Fig 3. 
Characterization of GA using SD-OCT. A. 2-D OCT of a healthy eye showing individual 
retinal layers. B. 2-D OCT of an eye with GA showing degradation of RPE and neural layers 
and enhancement of signal from the choroid. C. 2-D OCT for quantitation of GA 
progression. Highlighted green area corresponds to retina lost to atrophy from baseline to 
follow-up, allowing measurement of change in retinal thickness and GA lesion boundaries. 
RNFL, retina nerve fiber layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, 
inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer (1 = external 
limiting membrane; 2 = inner photoreceptor layer; 3 = photoreceptor outer segment-RPE 
interdigitation; 4 = RPE-Bruch’s membrane complex; 5 = choriocapillaris and choroid).
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Fig 4. 
Schematic illustration of the assessment of retinal function using mfERG in healthy retina 
(top) and in GA (bottom). When the mfERG map is superimposed on the CFP image, the 
color gradient of the mfERG grid shows the most intense signal in healthy retina at the 
fovea. In eyes with AMD, decreasing retinal function is shown as darker colors in areas 
corresponding to GA.
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Fig 5. 
Measurement of retinal function in GA using microperimetry. Color-coded map of retinal 
sensitivity (top) shows loss of retinal function in darker areas that correspond to GA lesions 
as assessed by FAF (bottom). Worsening of retinal function is shown over time as lesion area 
expands from baseline (A), at 12 months (B), and at 24 months (C).
Sadda et al. Page 26
Retina. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sadda et al. Page 27
Ta
bl
e
O
ng
oi
ng
 P
ha
se
 2
 a
nd
 3
 C
lin
ic
al
 T
ria
ls 
Ev
al
ua
tin
g 
G
A
 le
sio
ns
 R
eg
ist
er
ed
 o
n 
Cl
in
ic
al
Tr
ia
ls.
go
v
 a
s 
o
f M
ar
ch
 1
, 2
01
6
St
ud
y 
N
am
e, 
N
C
T 
Id
en
tif
ie
r
St
ud
y 
Ty
pe
En
ro
llm
en
t
Pr
im
ar
y 
O
ut
co
m
e M
ea
su
re
*
A
 S
tu
dy
 In
v
es
tig
at
in
g 
th
e 
Ef
fic
ac
y 
an
d 
Sa
fe
ty
 o
f L
am
pa
liz
um
ab
 In
tra
v
itr
ea
l I
nje
cti
on
s 
in
 P
at
ie
nt
s W
ith
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
Se
co
nd
ar
y 
to
 A
ge
-R
el
at
ed
 M
ac
ul
ar
 D
eg
en
er
at
io
n 
(C
HR
O
M
A
), N
CT
02
24
74
79
Ph
as
e 
3 
In
te
rv
en
tio
na
l
93
6
Ch
an
ge
 in
 G
A
 a
re
a,
 a
s a
ss
es
se
d 
by
 F
A
F
A
 S
tu
dy
 In
v
es
tig
at
in
g 
th
e 
Sa
fe
ty
 a
nd
 E
ffi
ca
cy
 o
f L
am
pa
liz
um
ab
 In
tra
v
itr
ea
l I
nje
cti
on
s 
in
 P
at
ie
nt
s W
ith
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
Se
co
nd
ar
y 
to
 A
ge
-R
el
at
ed
 M
ac
ul
ar
 D
eg
en
er
at
io
n 
(S
PE
CT
RI
), N
CT
02
24
75
31
Ph
as
e 
3 
In
te
rv
en
tio
na
l
93
6
Ch
an
ge
 in
 G
A
 a
re
a,
 a
s a
ss
es
se
d 
by
 F
A
F
A
 P
ha
se
 2
b/
3 
M
ul
tic
en
te
r, 
R
an
do
m
iz
ed
, D
ou
bl
e-
M
as
ke
d,
 D
os
e-
Ra
ng
in
g 
St
ud
y 
Co
m
pa
rin
g 
th
e 
Ef
fic
ac
y 
an
d 
Sa
fe
ty
 o
f E
m
ix
us
ta
t H
yd
ro
ch
lo
rid
e 
(A
CU
-4
42
9) 
W
ith
 
Pl
ac
eb
o 
fo
r t
he
 T
re
at
m
en
t o
f G
eo
gr
ap
hi
c 
A
tro
ph
y 
A
ss
oc
ia
te
d 
W
ith
 D
ry
 A
ge
-R
el
at
ed
 
M
ac
ul
ar
 D
eg
en
er
at
io
n 
(S
EA
TT
LE
), N
CT
01
80
28
66
Ph
as
e 
2b
/3
 In
te
rv
en
tio
na
l
48
0
Ch
an
ge
 in
 G
A
 a
re
a
A
 R
an
do
m
iz
ed
, D
ou
bl
e 
Bl
in
d,
 P
la
ce
bo
 C
on
tro
lle
d 
St
ud
y 
Ev
al
ua
tin
g 
O
RA
CE
A
®
 
in
 
Su
bje
cts
 W
ith
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
Se
co
nd
ar
y 
to
 N
on
-E
xu
da
tiv
e 
A
ge
-R
el
at
ed
 M
ac
ul
ar
 
D
eg
en
er
at
io
n 
(T
O
G
A
), N
CT
01
78
29
89
Ph
as
e 
2/
3 
In
te
rv
en
tio
na
l
28
6
R
at
e 
of
 e
nl
ar
ge
m
en
t i
n 
ar
ea
 o
f g
eo
gr
ap
hi
c 
at
ro
ph
y 
in
 th
e 
stu
dy
 
ey
e 
du
rin
g 
th
e 
tre
at
m
en
t p
er
io
d
A
 S
af
et
y 
an
d 
Ef
fic
ac
y 
St
ud
y 
of
 B
rim
on
id
in
e 
In
tra
v
itr
ea
l I
m
pl
an
t i
n 
G
eo
gr
ap
hi
c 
A
tro
ph
y 
Se
co
nd
ar
y 
to
 A
ge
-re
la
te
d 
M
ac
ul
ar
 D
eg
en
er
at
io
n 
(B
EA
CO
N
), N
CT
02
08
70
85
Ph
as
e 
2 
In
te
rv
en
tio
na
l
30
0
Ch
an
ge
 fr
om
 b
as
el
in
e 
in
 a
tro
ph
ic
 le
sio
n 
ar
ea
 in
 th
e 
stu
dy
 ey
e
A
 S
tu
dy
 to
 E
va
lu
at
e 
th
e 
Sa
fe
ty
 a
nd
 C
lin
ic
al
 R
es
po
ns
e 
of
 S
ub
re
tin
al
 A
dm
in
ist
ra
tio
n 
of
 
CN
TO
 2
47
6 
in
 P
ar
tic
ip
an
ts 
W
ith
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
(P
RE
LU
DE
), N
CT
02
65
90
98
Ph
as
e 
2 
In
te
rv
en
tio
na
l
25
5
Ch
an
ge
 in
 G
A
 le
sio
n 
gr
ow
th
 a
s m
ea
su
re
d 
by
 F
A
F 
(se
co
nd
ary
 
en
dp
oi
nt
)
St
ud
y 
of
 A
PL
-2
 T
he
ra
py
 in
 P
at
ie
nt
s G
eo
gr
ap
hi
c 
A
tro
ph
y 
(F
IL
LY
), N
CT
02
50
33
32
Ph
as
e 
2 
In
te
rv
en
tio
na
l
24
0
Ch
an
ge
 in
 sq
ua
re
 ro
ot
 G
A
 le
sio
n 
siz
e 
fro
m
 b
as
el
in
e,
 a
s m
ea
su
re
d 
by
 F
A
F
Cl
in
ic
al
 S
tu
dy
 to
 In
v
es
tig
at
e 
Sa
fe
ty
 a
nd
 E
ffi
ca
cy
 o
f G
SK
93
37
76
 in
 A
du
lt 
Pa
tie
nt
s W
ith
 
G
eo
gr
ap
hi
c 
A
tro
ph
y 
Se
co
nd
ar
y 
to
 A
ge
-re
la
te
d 
M
ac
ul
ar
 D
eg
en
er
at
io
n,
 N
CT
01
34
29
26
Ph
as
e 
2 
In
te
rv
en
tio
na
l
18
4
R
at
e 
of
 c
ha
ng
e 
in
 a
re
a 
of
 G
A
 fr
om
 b
as
el
in
e
CL
G
56
1 
Pr
oo
f-o
f-C
on
ce
pt
 S
tu
dy
 as
 a 
M
on
ot
he
ra
py
 a
nd
 in
 C
om
bi
na
tio
n 
W
ith
 L
FG
31
6 
in
 S
ub
jec
ts 
W
ith
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
(G
A)
, N
CT
02
51
59
42
Ph
as
e 
2 
In
te
rv
en
tio
na
l
11
4
(1)
 Sa
fet
y e
v
en
ts
 a
nd
 (2
) c
ha
ng
e i
n G
A 
les
ion
 si
ze
 fr
om
 ba
sel
ine
, 
as
 m
ea
su
re
d 
by
 F
A
F
A
 S
tu
dy
 o
f L
am
pa
liz
um
ab
 In
tra
v
itr
ea
l I
nje
cti
on
s A
dm
ini
ste
red
 Ev
er
y 
Tw
o
 W
ee
ks
 o
r 
Ev
er
y 
Fo
u
r 
W
ee
ks
 to
 P
at
ie
nt
s W
ith
 G
eo
gr
ap
hi
c 
A
tro
ph
y,
 
N
CT
02
28
85
59
Ph
as
e 
2 
In
te
rv
en
tio
na
l
90
M
ea
n 
ch
an
ge
 in
 G
A
 a
re
a,
 a
s m
ea
su
re
d 
by
 F
A
F
Th
e 
Ef
fe
ct
 o
f M
et
fo
rm
in
 o
n 
th
e 
Pr
og
re
ss
io
n 
of
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
in
 P
at
ie
nt
s W
ith
 
A
ge
-re
la
te
d 
M
ac
ul
ar
 D
eg
en
er
at
io
n,
 N
CT
02
68
45
78
Ph
as
e 
2 
In
te
rv
en
tio
na
l
10
0
Ch
an
ge
 in
 G
A
 a
re
a 
as
 m
ea
su
re
d 
by
 F
A
F
Ev
al
ua
tio
n 
of
 O
ra
l M
in
oc
yc
lin
e 
in
 th
e 
Tr
ea
tm
en
t o
f G
eo
gr
ap
hi
c 
A
tro
ph
y 
A
ss
oc
ia
te
d 
W
ith
 A
ge
-R
el
at
ed
 M
ac
ul
ar
 D
eg
en
er
at
io
n,
 N
CT
02
56
49
78
Ph
as
e 
2 
In
te
rv
en
tio
na
l
62
R
at
e 
of
 c
ha
ng
e 
in
 G
A
 a
re
a 
as
 m
ea
su
re
d 
by
 F
A
F
A
 M
ul
tic
en
te
r, 
Pr
os
pe
ct
iv
e 
Ep
id
em
io
lo
gi
c 
St
ud
y 
of
 th
e 
Pr
og
re
ss
io
n 
of
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
Se
co
nd
ar
y 
to
 A
ge
-R
el
at
ed
 M
ac
ul
ar
 D
eg
en
er
at
io
n 
(P
RO
X
IM
A
-A
), 
N
CT
02
47
93
86
O
bs
er
va
tio
na
l
36
0
Pr
im
ar
y 
ou
tc
om
es
 ev
al
ua
te
 v
isu
al
 fu
nc
tio
n;
 se
co
nd
ar
y 
ou
tc
om
es
 
in
cl
ud
e 
m
ea
su
re
m
en
t o
f G
A
 a
re
a 
by
 F
A
F
Pr
os
pe
ct
iv
e 
N
at
ur
al
 H
ist
or
y 
St
ud
y 
of
 F
un
du
s A
ut
of
lu
or
es
ce
nc
e 
Im
ag
in
g 
in
 A
ge
-re
la
te
d 
M
ac
ul
ar
 D
eg
en
er
at
io
n 
(FA
M
-S
tu
dy
) U
sin
g C
on
foc
al 
Sc
an
nin
g L
ase
r O
ph
tha
lm
os
co
py
,
 
N
CT
00
39
36
92
O
bs
er
va
tio
na
l
30
0
Ch
an
ge
 o
f G
A
 si
ze
 fr
om
 b
as
el
in
e,
 a
s a
ss
es
se
d 
by
 F
A
F
A
n 
Ep
id
em
io
lo
gi
c 
St
ud
y 
of
 D
ise
as
e 
Pr
og
re
ss
io
n 
in
 P
at
ie
nt
s W
ith
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
Se
co
nd
ar
y 
to
 A
ge
-R
el
at
ed
 M
ac
ul
ar
 D
eg
en
er
at
io
n 
(P
rox
im
a B
), N
CT
02
39
90
72
O
bs
er
va
tio
na
l
20
0
Ch
an
ge
 in
 G
A
 a
re
a,
 a
s a
ss
es
se
d 
by
 F
A
F
Retina. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sadda et al. Page 28
St
ud
y 
N
am
e, 
N
C
T 
Id
en
tif
ie
r
St
ud
y 
Ty
pe
En
ro
llm
en
t
Pr
im
ar
y 
O
ut
co
m
e M
ea
su
re
*
D
ire
ct
io
na
l S
pr
ea
d 
in
 G
eo
gr
ap
hi
c 
A
tro
ph
y 
(D
SG
A)
, N
CT
02
05
19
98
O
bs
er
va
tio
na
l
13
0
Ch
an
ge
 o
f G
A
 si
ze
 fr
om
 b
as
el
in
e
*
U
nl
es
s o
th
er
w
ise
 sp
ec
ifi
ed
 a
s a
 se
co
nd
ar
y 
en
dp
oi
nt
Retina. Author manuscript; available in PMC 2017 October 01.
